Millipore Sigma Vibrant Logo

508316 CTAP - CAS 103429-32-9 - Calbiochem

概述

Replacement Information

重要规格表

CAS #Empirical Formula
103429-32-9C₅₁H₆₉N₁₃O₁₁S₂

价格及供货情况

产品目录编号 库存情况包装 数量 / 包装 价格 数量
5.08316.0001
正在查询供货情况......
目前缺货
目前缺货
有货 
停产
少量现货
供货情况有待确认
    其余:另行通知
      其余:另行通知
      另行通知
      联系客户服务
      Contact Customer Service

      玻璃瓶 1 mg
      正在检索价格......
      无法检索价格。
      最小订购数量为倍数
      Maximum Quantity is
      以订单确认为准 更多信息
      您节约了 ()。
       
      Request Pricing
      Description
      OverviewA highly potent octapeptide that acts as a selective and brain penetrating bioavailable µ opioid receptor antagonist (IC50 = 3.5 nM). Used in studies of reward systems and additions.
      Catalogue Number508316
      Brand Family Calbiochem®
      Synonymsµ opioid receptor antagonist, CTAP
      References
      ReferencesPerry, C., et al., 2013. Behav. Neurosci. 127, 535.
      Burkett, J. et al. 2011. Neuropsychopharm. 36, 2200.
      Steinmiller, L., et al., 2008. Psychopharmacol. (Berl). 195, 497.
      Sterious, S., et al., 2003. J. Pharmacol. Exp. Ther. 304, 301.
      Abbruscato, T., et al. 1997. J. Pharmacol. 280, 402.
      Product Information
      CAS number103429-32-9
      FormOff-white solid
      Hill FormulaC₅₁H₆₉N₁₃O₁₁S₂
      Chemical formulaC₅₁H₆₉N₁₃O₁₁S₂
      Quality LevelMQ100
      Applications
      Biological Information
      Primary Targetu Opioid receptpr
      Primary Target IC<sub>50</sub>3.5 nM
      Purity≥95% by HPLC
      Physicochemical Information
      Peptide SequenceD-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (2-7 disulfide bond)
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
      Toxicity Standard Handling
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      产品目录编号 GTIN
      5.08316.0001 04055977261844

      Documentation

      CTAP - CAS 103429-32-9 - Calbiochem MSDS

      职位

      物料安全数据表 (MSDS) 

      CTAP - CAS 103429-32-9 - Calbiochem 分析证书

      标题批号
      508316

      参考

      参考信息概述
      Perry, C., et al., 2013. Behav. Neurosci. 127, 535.
      Burkett, J. et al. 2011. Neuropsychopharm. 36, 2200.
      Steinmiller, L., et al., 2008. Psychopharmacol. (Berl). 195, 497.
      Sterious, S., et al., 2003. J. Pharmacol. Exp. Ther. 304, 301.
      Abbruscato, T., et al. 1997. J. Pharmacol. 280, 402.
      数据表

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision25-October-2013 JSW
      Synonymsµ opioid receptor antagonist, CTAP
      DescriptionA highly potent octapeptide that acts as a selective and brain penetrating bioavailable µ opioid receptor antagonist (IC50 = 3.5 nM). Used in studies of reward systems and additions.
      FormOff-white solid
      CAS number103429-32-9
      Chemical formulaC₅₁H₆₉N₁₃O₁₁S₂
      Peptide SequenceD-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (2-7 disulfide bond)
      Purity≥95% by HPLC
      SolubilityH₂O
      Storage Protect from light
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesPerry, C., et al., 2013. Behav. Neurosci. 127, 535.
      Burkett, J. et al. 2011. Neuropsychopharm. 36, 2200.
      Steinmiller, L., et al., 2008. Psychopharmacol. (Berl). 195, 497.
      Sterious, S., et al., 2003. J. Pharmacol. Exp. Ther. 304, 301.
      Abbruscato, T., et al. 1997. J. Pharmacol. 280, 402.